Sphere Fluidics

Sphere Fluidics creates advanced single cell analysis systems for biotherapeutic discovery.

Cambridge, UK—Website

£33.7MTotal raised

Sphere Fluidics develops and commercialises single cell analysis systems powered by proprietary picodroplet technology. The company supports global biotherapeutic discovery and development through its automated platforms.

Team

Frank Craig

CEO

Frank chairs BioChannel Partners and previously served as chief executive of Sphere Fluidics and Life Sciences Consultancy.

Zoe Nilsson

Zoe brings marketing experience from bit.bio, Sphere Fluidics, and Axol Bioscience.

Andrew Mackintosh

Chairman

Investors

Series B28 October 2021
£30.0M
Sofinnova PartnersLead
RG
Redmile GroupLead
Series D+10 June 2019
£3.7M
GW
Greenwood Way CapitalLead
24HaymarketLead

Funding history

Series B28 October 2021

£30.0M

Sphere Fluidics raises £30m in Series B funding to accelerate international sales and product development.

The investment round was co-led by Sofinnova Partners and Redmile Group to fund global expansion and research programmes.

Series D+10 June 2019

£3.7M

Sphere Fluidics raises £3.7m from Greenwood Way Capital and 24Haymarket to fund expansion.

Greenwood Way Capital and 24Haymarket led the financing round to support international expansion and operations.